Targeting the Cell Surfaceome of Aggressive Neuroendocrine Prostate Cancer
Abstract
In this reporting period, we have performed transcriptomic and cell surface proteomic profiling of a panel of human prostate cancer cell lines and integrated these data sets to nominate high-confidence cell surface antigens associated with neuroendocrine prostate cancer(NEPC) and prostate adenocarcinoma (PrAd). Validation of candidate antigens is ongoing but several have demonstrated prostate cancer subtype-specific protein expression based on immunoblotting, immunohistochemistry, and flow cytometry of prostate cancer cell lines, xenografts, and clinical prostate cancer tissues. For example, we have characterized CEACAM5(carcinoembryonic antigen 5) as a cell surface marker expressed in 60 of NEPC but not inPrAd. This finding has led to new projects in the laboratory with potential for clinical translation related to therapeutically targeting CEACAM5-positive NEPC with an antibody-drug conjugate or chimeric antigen receptor T cell immunotherapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2018
- Accession Number
- AD1053934
Entities
People
- John K Lee
Organizations
- University of California, Los Angeles